Sorrento Therapeutics Inc. shareholders lack grounds to appeal a bankruptcy court’s decision blocking a broad probe into whether company attorneys sought to exploit a romantic relationship involving ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly ...

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report) today and set a price target of C$6.25. The company’s shares opened today at $4.17.

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against other stocks that are ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any ...